Huang Junjie, Chen Hanxu, Li Ning, Liu Panmiao, Yang Jianjun, Zhao Yuanjin
Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, China.
Department of Anesthesiology, Pain and Perioperative Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Bioact Mater. 2025 Jun 13;52:338-365. doi: 10.1016/j.bioactmat.2025.06.005. eCollection 2025 Oct.
Extracellular vesicles (EVs), which carry bioactive components such as proteins and nucleic acids, reflect the physiological state of their parent cells and play a key role in mediating complex intercellular signaling. Leveraging these unique characteristics, researchers have explored their potential applications in cell therapy, non-invasive biopsies, and tissue regeneration. Therefore, standardized and scalable methods for EVs production and purification are crucial for clinical application and therapeutic settings. However, the limited yields of traditional production and isolation methods have hampered full potential of EVs. In this review, we will introduce strategies aimed at enhancing EV production include optimizing cell yield, expanding cell culture scale, and exploring alternative EVs production sources such as non-mammalian organisms and artificially produced vesicles. Various approaches as well as the bioreactors for controlling cell culture to enhance EVs production, will be introduced in detail. These approaches include regulation of culture parameters, culture medium components, and external stimuli. Additionally, the comparison between traditional ultracentrifugation methods and advance microfluidic isolating methods will be analyzed and discussed. Finally, we will introduce the potential challenges of transitioning EVs from basic research to clinical application and further discuss the future prospects. As the technology advances and different methods are integrated, there is significant potential to enable large-scale EVs production and improve their clinical translation.
细胞外囊泡(EVs)携带蛋白质和核酸等生物活性成分,反映其母细胞的生理状态,并在介导复杂的细胞间信号传导中发挥关键作用。利用这些独特特性,研究人员探索了它们在细胞治疗、无创活检和组织再生中的潜在应用。因此,标准化且可扩展的EVs生产和纯化方法对于临床应用和治疗环境至关重要。然而,传统生产和分离方法的产量有限,阻碍了EVs的全部潜力。在本综述中,我们将介绍旨在提高EVs产量的策略,包括优化细胞产量、扩大细胞培养规模,以及探索非哺乳动物生物体和人工生产的囊泡等替代EVs生产来源。将详细介绍各种方法以及用于控制细胞培养以提高EVs产量的生物反应器。这些方法包括调节培养参数、培养基成分和外部刺激。此外,还将分析和讨论传统超速离心方法与先进微流体分离方法之间的比较。最后,我们将介绍将EVs从基础研究转化为临床应用的潜在挑战,并进一步讨论未来前景。随着技术的进步和不同方法的整合,实现大规模EVs生产并改善其临床转化具有巨大潜力。
Bioact Mater. 2025-6-13
Tissue Eng Regen Med. 2025-6-5
Arch Ital Urol Androl. 2025-6-30
Cochrane Database Syst Rev. 2021-4-19
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024
Cochrane Database Syst Rev. 2020-1-9
Cochrane Database Syst Rev. 2018-2-6
Nat Nanotechnol. 2025-1